Biocon Limited, an innovation-led global biopharmaceutical company headquartered in Bengaluru, has entered into an out-licensing agreement with Ajanta Pharma Ltd, a specialty pharmaceutical formulations company, for marketing rights to its vertically integrated drug Semaglutide, which is used to improve glycaemic control in adults with type-2 diabetes.
Under the terms of the deal, Biocon will supply Semaglutide to Ajanta for exclusive marketing rights in 23 countries and semi-exclusive marketing rights in three additional countries across Africa, the Middle East and Central Asia. Ajanta Pharma has built a branded generics business in more than 30 countries across Africa, South-East Asia, Central Asia and the Middle East, with established presence in therapeutic areas such as cardiology, anti-diabetes, ophthalmology, antibiotics, anti-malarial treatments, pain, gynaecology, paediatrics and general health products.
The agreement is designed to expand the geographic reach of Semaglutide into emerging and underserved markets by leveraging Ajanta’s commercial infrastructure and deep market presence, enabling broader and more affordable access to this important diabetes therapy.
Ajanta plans to commercialise the product once it receives the necessary regulatory approvals, which are expected in late 2026 or early 2027, and will utilise its field force of over 2,000 medical representatives to drive uptake and build Semaglutide into a high-growth brand in the specified regions.
The collaboration represents a strategic step in expanding the global footprint of Biocon’s GLP-1 portfolio and maximising the value of its scientific investments in complex peptide development by bringing advanced treatments to new markets through a partner with strong on-ground reach.
